Literature DB >> 8682594

A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients.

M Span1, P T Moerkerk, A F De Goeij, J W Arends.   

Abstract

Point mutations in codon 12, 13, and 61 of the K-ras gene are an early event in tumorigenesis of colorectal cancer, but the impact of number, type, and position of such mutations on the progression of adenomas as well as the clinical behaviour of colorectal carcinomas is not clearly established. A series of 35 adenomas and 117 carcinomas at various stages was subjected to single-strand conformation polymorphism (SSCP) to analyse type, position and number of exon-I K-ras point mutations and to relate the results with patients survival. From our data we conclude that the number of K-ras point mutated tumors shows a trend to increase with tumor progression. The number of multiple K-ras point mutations, however, significantly increases with stage. Most mutations occur in the 1st or 2nd base of codon 12, whereas point mutations in the 3rd base are rare. In adenomas mutations, particularly G-T transversions, in the K-ras gene could indicate a propensity to malignant transformation. G-A transitions and G-C transversions of the second base are associated with metastasized tumors. Regarding survival, patients with K-ras point mutated tumors did worse than their non-mutated counterparts. G-A transitions in the 1st and 2nd base and G-C transversions in the 2nd base were associated with a poor prognosis as compared with G-T transversions in both the 1st and 2nd base. Patient survival therefore is related to the occurrence and type, but not the location, of K-ras point mutations.

Entities:  

Mesh:

Year:  1996        PMID: 8682594     DOI: 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.0.CO;2-A

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.

Authors:  Timothy L Frankel; Efsevia Vakiani; Hari Nathan; Ronald P DeMatteo; T Peter Kingham; Peter J Allen; William R Jarnagin; Nancy E Kemeny; David B Solit; Michael I D'Angelica
Journal:  Cancer       Date:  2016-10-13       Impact factor: 6.860

2.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

Authors:  Takeshi Ogura; Kenji Yamao; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Hiroshi Imaoka; Akira Sawaki; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tsutomu Tanaka; Yasuhiro Shimizu; Vikram Bhatia; Kazuhide Higuchi; Waki Hosoda; Yasushi Yatabe
Journal:  J Gastroenterol       Date:  2012-09-15       Impact factor: 7.527

3.  APC mutations are sufficient for the growth of early colorectal adenomas.

Authors:  H Lamlum; A Papadopoulou; M Ilyas; A Rowan; C Gillet; A Hanby; I Talbot; W Bodmer; I Tomlinson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 4.  What we could do now: molecular pathology of colorectal cancer.

Authors:  R S Houlston
Journal:  Mol Pathol       Date:  2001-08

Review 5.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

6.  Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.

Authors:  Sun-Young Jun; Misung Kim; Mi Jin Gu; Young Kyung Bae; Hee-Kyung Chang; Eun Sun Jung; Kee-Taek Jang; Jihun Kim; Eunsil Yu; Dae Woon Eom; Seung-Mo Hong
Journal:  Mod Pathol       Date:  2016-02-19       Impact factor: 7.842

Review 7.  Genetic prognostic markers in colorectal cancer.

Authors:  R S Houlston; I P Tomlinson
Journal:  Mol Pathol       Date:  1997-12

8.  KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.

Authors:  Tao Fu; Angela A Guzzetta; Jana Jeschke; Rajita Vatapalli; Pujan Dave; Craig M Hooker; Richard Morgan; Christine A Iacobuzio-Donahue; Baohua Liu; Nita Ahuja
Journal:  Int J Cancer       Date:  2013-01-18       Impact factor: 7.396

9.  Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Authors:  Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones
Journal:  Clin Colorectal Cancer       Date:  2013-06-14       Impact factor: 4.481

10.  Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.

Authors:  Elisabeth Pérez-Ruiz; A Rueda; T Pereda; J Alcaide; D Bautista; F Rivas-Ruiz; R Villatoro; D Pérez; M Redondo
Journal:  Tumour Biol       Date:  2012-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.